.

New Deal

New Deal

Announced

20 Jun 2017

Completed

15 Aug 2017

BRIDGEBIO PHARMA LLC / VIKING GLOBAL OPPORTUNITIES / PERCEPTIVE LIFE SCIENCES / KKR & CO / JANUS CAPITAL MANAGEMENT LLC / AISLING CAPITAL LLC / AIG ASSET MANAGEMENT (U.S.) LLC / Acquisition / Private

Financials

Transaction Value-

Consideration Type-

Capital Owned-

Capital Bid For-

EV/Sales-

EV/EBITDA-

Share Price Premium-

One Off Charge-

Bridgebio Pharma

target

Bridgebio Pharma

bidder

Aig Asset Management (u.s.)

Aisling Capital

bidder

Aisling Capital

bidder

Janus Capital Management

Kkr & Co

bidder

Kkr & Co

bidder

Perceptive Life Sciences

Viking Global Investors

bidder

Viking Global Investors

Sources

Tags

pharmaceuticals

Pharmaceuticals

United States

Acquisition

Private

Completed

Friendly

Single Bidder

Private Equity

Synopsis

Equity investment by KKR Genetic Disorder in BridgeBio Pharma, a developer of precision medicinal therapies for the treatment of genetic pediatric diseases.

Service Providers (2)

Latham & Watkins

legal advisors

Latham & Watkins

Latham & Watkins

legal advisors

Latham & Watkins

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.